hat
Methandrostenolòn / Dianabol se yon substra pou aromatase epi yo ka metabolize nan methylestradiol nan estwojèn (17α-methylestradiol). Pandan ke se pousantaj la nan aromatizasyon redwi relatif ak sa yo ki pou testostewòn oswa methyltestosterone, estwojèn a pwodwi se metabolis ki reziste yo e pakonsekan metandienone kenbe modèn aktivite estwojèn. Kòm sa yo, li ka lakòz efè segondè tankou gynecomastia ak retansyon likid. yon antiestrogen tankou yon inibitè aromatase tankou anastrozole oswa yon modulator récepteurs selektif estwojèn tankou tamoksifèn ka diminye oswa anpeche efè segondè estwojenik. Metandienone pa gen okenn aktivite progestogenic.
eng
Methandrostenolone/Dianabol is a substrate for aromatase and can be metabolized into the estrogen methylestradiol (17α-methylestradiol). While the rate of aromatization is reduced relative to that for testosterone or methyltestosterone, the estrogen produced is metabolism-resistant and hence metandienone retains moderate estrogenic activity.As such, it can cause side effects such as gynecomastia and fluid retention.The co-administration of an antiestrogen such as an aromatase inhibitor like anastrozole or a selective estrogen receptor modulator like tamoxifen can reduce or prevent such estrogenic side effects. Metandienone has no progestogenic activity.